Journal: Cancer Immunology, Immunotherapy

Article Title: Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data

doi: 10.1007/s00262-024-03658-w

Figure Lengend Snippet: Identification of hub genes in CRC. A RSF and expression-level analyses of prognosis-related genes. B Expression levels and distribution of TRIP6, PTTG1IP, PTPN6, GDE1, SEC61G , and CYP2W1 in different tumor subtypes. C Expression levels of 6 DEGs between CRC tissues and normal tissues. D ROC curves representing disease predictions according to six key genes. E K‒M curves showing OS of patients with CRC grouped according to the expression levels of key genes

Article Snippet: The membranes were then incubated at 4 °C overnight with the following primary antibodies at the indicated dilutions: anti-CYP2W1 (1:500, PA5-101315, Invitrogen), anti-GDE1 (1:1000, PA5-43012, Invitrogen), anti-PTPN6 (1:1000, ab124942, Abcam), anti-PTTG1IP (1:500, ab128040, Abcam), anti-SEC61G (1:500, PA5-21384, Invitrogen), and anti-TRIP6 (1:500, ab137478, Abcam) antibodies.

Techniques: Expressing

Journal: BMC Cancer

Article Title: PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival

doi: 10.1186/s12885-017-3694-6

Figure Lengend Snippet: Examples of immunoexpression patterns of PTTG1IP and securin in breast carcinomas. PTTG1IP was observed as a diffuse cytoplasmic staining, and scored based on the extent of positive cancer cells as negative (score 0) and mild to strong positivity (scores 1+ − 3+). Securin was observed both in the nucleus and cytoplasm of the cancer cells and classified according to the fraction of positively-staining cancer cells (<10% vs. ≥10% of cancer cells). Examples of nuclear and cytoplasmic staining patterns are indicated with arrows. (200× magnification)

Article Snippet: The immunohistochemical (IHC) staining of PTTG1IP was performed with rabbit polyclonal anti-PTTG1IP antibody (Abcam, Cambridge, UK, ab128040) on an automated immunostaining Discovery XT machine (Roche Diagnostics/Ventana Medical Systems, Tucson, AZ, USA).

Techniques: Staining

Journal: BMC Cancer

Article Title: PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival

doi: 10.1186/s12885-017-3694-6

Figure Lengend Snippet: Photomicrographs of PTTG1IP and securin immunoexpression in benign breast epithelium and in breast carcinomas representing luminal, HER2-amplified and triple-negative subtypes. IF double staining demonstrates the co-localization of PTTG1IP and securin in benign and malignant epithelium (red signal PTTG1IP and green signal securin). (200× magnification)

Article Snippet: The immunohistochemical (IHC) staining of PTTG1IP was performed with rabbit polyclonal anti-PTTG1IP antibody (Abcam, Cambridge, UK, ab128040) on an automated immunostaining Discovery XT machine (Roche Diagnostics/Ventana Medical Systems, Tucson, AZ, USA).

Techniques: Amplification, Double Staining

Journal: BMC Cancer

Article Title: PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival

doi: 10.1186/s12885-017-3694-6

Figure Lengend Snippet: Kaplan-Meier analysis of breast cancer survival based on all breast cancer subtypes ( n = 401) demonstrating survival difference associated with PTTG1IP immunoexpression ( a ) and the combination of the immunoexpressions of PTTG1IP and securin ( b )

Article Snippet: The immunohistochemical (IHC) staining of PTTG1IP was performed with rabbit polyclonal anti-PTTG1IP antibody (Abcam, Cambridge, UK, ab128040) on an automated immunostaining Discovery XT machine (Roche Diagnostics/Ventana Medical Systems, Tucson, AZ, USA).

Techniques:

Journal: BMC Cancer

Article Title: PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival

doi: 10.1186/s12885-017-3694-6

Figure Lengend Snippet: Multivariate analyses for PTTG1IP and securin immunohistochemistry, and established prognosticators a

Article Snippet: The immunohistochemical (IHC) staining of PTTG1IP was performed with rabbit polyclonal anti-PTTG1IP antibody (Abcam, Cambridge, UK, ab128040) on an automated immunostaining Discovery XT machine (Roche Diagnostics/Ventana Medical Systems, Tucson, AZ, USA).

Techniques: Immunohistochemistry

Journal: BMC Cancer

Article Title: PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival

doi: 10.1186/s12885-017-3694-6

Figure Lengend Snippet: PTTG1IP and securin in breast carcinoma

Article Snippet: The immunohistochemical (IHC) staining of PTTG1IP was performed with rabbit polyclonal anti-PTTG1IP antibody (Abcam, Cambridge, UK, ab128040) on an automated immunostaining Discovery XT machine (Roche Diagnostics/Ventana Medical Systems, Tucson, AZ, USA).

Techniques: